Results 171 to 180 of about 1,948,252 (310)

Health care workers' experiences of exercise in forensic psychiatry: a qualitative focus group study. [PDF]

Int J Qual Stud Health Well-being
Bergman H, Gutke A, Andiné P, Degl' Innocenti A, Nilsson T, Thomeé R, Wijk H.   +6 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Sexual and Gender Minorities in Organ and Tissue Donation and Transplantation (OTDT): A Survey of Canadian OTDT Health Care Workers. [PDF]

Can J Kidney Health Dis
Leeies M, Hrymak C, Mooney O, Vazquez-Grande G, Carta T, Ho J, Christie E, Doucette K, Chandler J, Brodovsky S, Dhanani S, Weiss MJ, Gentile M, Sutha K, Lee TH, Collister D.   +15 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

A Qualitative Study of Norwegian Care Institutions Health Care Workers’ Experiences of Ad Hoc Ethical Reflection During the Workday

Journal of Multidisciplinary Healthcare
Håkon Johansen,1,2,* Ann Karin Helgesen,1 Ingrid Femdal1,* 1Faculty of Health, Welfare and Organisation, Østfold University College, Fredrikstad, Norway; 2Centre for Development of Institutional and Home Care Services Østfold, Indre ...
Johansen H, Helgesen AK, Femdal I
doaj  

Organizational Readiness for Change in the Era of Smart Hospital Wards: Qualitative Study of Health Care Workers' Insights. [PDF]

JMIR Hum Factors
Lim HW, Sumner J, Ang A, Keck C, Chew EHH, Yip AW.   +5 more
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

COVID-19 among health care workers in Brazil: prevalence and disparities based on respondent-driven sampling. [PDF]

Rev Saude Publica
Kerr L, Leal M, Almeida RLF, Silva AZD, Frota CC, Lima LNGC, Cruz LN, Albuquerque MFM, Cohen M, Ximenes RAA, Souza WV, Veras MASM, Gomes JL, Pires Neto RDJ, Galvão MTG, Pinheiro PNDC, Montarroyos UR, Pereira CR, Miranda-Filho DB, Souza Junior PRB, Araújo TVB, Santos Neto PMD, Braga C, Martelli CMT, Kendall C.   +24 more
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source